GLUE - Latest News
Monte Rosa Therapeutics, Inc. (GLUE), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.23B. Beta to the broader market is 1.62.
The article list below shows the most recent GLUE headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent GLUE Headlines
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
zacks.com - May 7, 2026
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0. 45 per share versus the Zacks Consensus Estimate of a loss of $0.
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
globenewswire.com - May 7, 2026
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; reado
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - May 5, 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecu
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
fool.com - Apr 21, 2026
A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a weighted average price of around $17. 64 per share on
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
globenewswire.com - Apr 20, 2026
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers
How News Affects GLUE Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track GLUE's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked GLUE news questions
- What is the latest GLUE news headline?
- The most recent GLUE headline (May 7, 2026) is "Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the GLUE news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What GLUE news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual GLUE options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.